NCT00352794View on ClinicalTrials.gov

Lenalidomide for Patients With Myelofibrosis (MF)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 7, 2006

Primary Completion Date

March 8, 2018

Study Completion Date

March 8, 2018

Conditions
Myelofibrosis
Interventions
DRUG

Lenalidomide

Oral 10 mg daily/days 1-21 of 28 day cycle

DRUG

Prednisone

Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER